Chronic Complications of Cholestasis: Evaluation and Management
- PMID: 30259851
- DOI: 10.1016/j.cld.2018.03.014
Chronic Complications of Cholestasis: Evaluation and Management
Abstract
Patients with primary biliary cholangitis (PBC) are at risk for various harmful consequences of chronic cholestasis. These include fat-soluble vitamin deficiency, even in the setting of macronutrient sufficiency, as well as metabolic bone disease, including osteoporosis with fractures. Hyperlipidemia is often present and less commonly associated with risk of cardiovascular event; however, the long-term effect of new emerging therapies for PBC remains to be determined. Patients with PBC also have infrequent but notable risk of portal hypertension despite early-stage disease. This review discusses the background, evaluation, and practical management of these complications of chronic cholestasis.
Keywords: Cholestasis; Fat-soluble vitamin deficiency; Hepatocellular carcinoma; Hyperlipidemia; Malabsorption; Metabolic bone disease; Portal hypertension; Primary biliary cholangitis.
Copyright © 2018 Elsevier Inc. All rights reserved.
Similar articles
-
Treatment of primary biliary cirrhosis.Semin Liver Dis. 1985 Aug;5(3):228-40. doi: 10.1055/s-2008-1040620. Semin Liver Dis. 1985. PMID: 3901272 Review. No abstract available.
-
Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis.Clin Liver Dis. 2003 Nov;7(4):901-10. doi: 10.1016/s1089-3261(03)00097-7. Clin Liver Dis. 2003. PMID: 14594136 Review.
-
Vitamin E deficiency in primary biliary cirrhosis: gastrointestinal malabsorption, frequency and relationship to other lipid-soluble vitamins.Hepatology. 1989 Apr;9(4):525-31. doi: 10.1002/hep.1840090403. Hepatology. 1989. PMID: 2925155
-
Nutritional deficiencies during normal growth.Pediatr Clin North Am. 2009 Oct;56(5):1035-53. doi: 10.1016/j.pcl.2009.07.004. Pediatr Clin North Am. 2009. PMID: 19931062 Review.
-
The prevalence of fat-soluble vitamin deficiencies and a decreased bone mass in patients with chronic pancreatitis.Pancreatology. 2013 May-Jun;13(3):238-42. doi: 10.1016/j.pan.2013.02.008. Epub 2013 Mar 4. Pancreatology. 2013. PMID: 23719594
Cited by
-
Gut microbiota and fecal metabolic signatures in rat models of disuse-induced osteoporosis.Front Cell Infect Microbiol. 2022 Dec 14;12:1018897. doi: 10.3389/fcimb.2022.1018897. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36590590 Free PMC article.
-
Nutritional Management of Cholestasis.Clin Liver Dis (Hoboken). 2020 Feb 25;15(1):9-12. doi: 10.1002/cld.865. eCollection 2020 Jan. Clin Liver Dis (Hoboken). 2020. PMID: 32104570 Free PMC article. Review.
-
Iqirvo for primary biliary cholangitis - efficacy, safety, and future directions.Ann Med Surg (Lond). 2025 Mar 20;87(5):2758-2762. doi: 10.1097/MS9.0000000000003183. eCollection 2025 May. Ann Med Surg (Lond). 2025. PMID: 40337437 Free PMC article. Review.
-
The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic review.Med Pharm Rep. 2024 Jan;97(1):12-25. doi: 10.15386/mpr-2629. Epub 2024 Jan 29. Med Pharm Rep. 2024. PMID: 38344336 Free PMC article. Review.
-
Determination of Optimal Vitamin D Dosage in Children with Cholestasis.BMC Pediatr. 2023 Jun 21;23(1):313. doi: 10.1186/s12887-023-04113-y. BMC Pediatr. 2023. PMID: 37344793 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical